Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative …
Clinical & Experimental Immunology, 2015 - academic.oup.com
Biopharmaceuticals (BPs) represent a rapidly growing class of approved and investigational
drug therapies that is contributing significantly to advancing treatment in multiple disease …
drug therapies that is contributing significantly to advancing treatment in multiple disease …
Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative …
B Rup, M Pallardy, D Sikkema, T Albert… - Clinical and …, 2015 - research.regionh.dk
Biopharmaceuticals (BPs) represent a rapidly growing class of approved and investigational
drug therapies that is contributing significantly to advancing treatment in multiple disease …
drug therapies that is contributing significantly to advancing treatment in multiple disease …
Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: Recommendations of the innovative …
B Rup, M Pallardy, D Sikkema, T Albert… - Clinical & …, 2015 - discovery.ucl.ac.uk
Biopharmaceuticals (BPs) represent a rapidly growing class of approved and investigational
drug therapies that is contributing significantly to advancing treatment in multiple disease …
drug therapies that is contributing significantly to advancing treatment in multiple disease …
Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative …
B Rup, M Pallardy, D Sikkema… - Clinical and …, 2015 - researchinformation.amsterdamumc …
Biopharmaceuticals (BPs) represent a rapidly growing class of approved and investigational
drug therapies that is contributing significantly to advancing treatment in multiple disease …
drug therapies that is contributing significantly to advancing treatment in multiple disease …
Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative …
B Rup, M Pallardy, D Sikkema, T Albert… - Clinical and …, 2015 - europepmc.org
Biopharmaceuticals (BPs) represent a rapidly growing class of approved and investigational
drug therapies that is contributing significantly to advancing treatment in multiple disease …
drug therapies that is contributing significantly to advancing treatment in multiple disease …
Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative …
B Rup, M Pallardy, D Sikkema, T Albert… - Clinical & …, 2015 - Wiley Online Library
Biopharmaceuticals (BPs) represent a rapidly growing class of approved and investigational
drug therapies that is contributing significantly to advancing treatment in multiple disease …
drug therapies that is contributing significantly to advancing treatment in multiple disease …
Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative …
B Rup, M Pallardy, D Sikkema, T Albert… - Clinical & …, 2015 - search.ebscohost.com
Biopharmaceuticals (BPs) represent a rapidly growing class of approved and investigational
drug therapies that is contributing significantly to advancing treatment in multiple disease …
drug therapies that is contributing significantly to advancing treatment in multiple disease …
Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative …
B Rup, M Pallardy, D Sikkema… - Clinical and …, 2015 - pubmed.ncbi.nlm.nih.gov
Biopharmaceuticals (BPs) represent a rapidly growing class of approved and investigational
drug therapies that is contributing significantly to advancing treatment in multiple disease …
drug therapies that is contributing significantly to advancing treatment in multiple disease …
Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative …
B Rup, M Pallardy, D Sikkema, T Albert, M Allez… - Clinical & Experimental …, 2015 - infona.pl
Biopharmaceuticals (BPs) represent a rapidly growing class of approved and investigational
drug therapies that is contributing significantly to advancing treatment in multiple disease …
drug therapies that is contributing significantly to advancing treatment in multiple disease …
[HTML][HTML] Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the …
B Rup, M Pallardy, D Sikkema, T Albert… - Clinical and …, 2015 - ncbi.nlm.nih.gov
Biopharmaceuticals (BPs) represent a rapidly growing class of approved and investigational
drug therapies that is contributing significantly to advancing treatment in multiple disease …
drug therapies that is contributing significantly to advancing treatment in multiple disease …